Skip to main content

Monday's Health Winners & Losers

CV Therapeutics shares rose after an analyst's comments about the impact of a possible bid.

Updated from 2:08 p.m. EDT

Shares of

CV Therapeutics


jumped nearly 5% after a Piper Jaffray analyst said a buyout could total about $9 a share. The analyst, however, said Piper has no opinion whether a bid for the company would be made. The stock closed up 39 cents to $8.27.



also rose after the company said it expects first-quarter earnings to triple on an adjusted basis, which would top analysts' expectations. MedImmune, which will report on May 3, cited stronger sales of its respiratory therapy drug, Synagis. Shares of MedImmune added 38 cents, or 1%, to $36.76.

On the other hand,

Ariad Pharmaceuticals


declined on disappointing drug news. The company said that feedback from the Food and Drug Administration for a designed Phase III clinical trial of oncology drug candidate AP23573 will delay patient enrollment from the second quarter to the third quarter of 2007. Ariad fell 62 cents, or 12.6%, to $4.32.


(NVAX) - Get Novavax, Inc. Report

stumbled after the company said late Thursday that Chief Financial Officer Jeffrey Church had resigned and will leave later this month. Len Stigliano has been named interim CFO. Shares of the biotech company fell 20 cents, or 6.8%, to $2.73.

Among other health care winners Monday,

TheStreet Recommends



soared 52. 7% to $5.68.



jumped 30.6% to $23.58.

Cell Genesys


surged 26.1% to $6.86.

Other decliners included


(AMGN) - Get Amgen Inc. Report

, which fell 2% to $57.19.



slid 0.9% to $82.64, and


(BIIB) - Get Biogen Inc. Report

eased 1.4% to $44.39.